Blair William & Co. IL Sells 1,531 Shares of Abbott Laboratories (NYSE:ABT)

Share on StockTwits

Blair William & Co. IL reduced its stake in Abbott Laboratories (NYSE:ABT) by 0.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,383,701 shares of the healthcare product maker’s stock after selling 1,531 shares during the quarter. Blair William & Co. IL owned about 0.08% of Abbott Laboratories worth $109,188,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the business. Manchester Financial Inc. raised its holdings in Abbott Laboratories by 17.3% in the 1st quarter. Manchester Financial Inc. now owns 700 shares of the healthcare product maker’s stock valued at $55,000 after acquiring an additional 103 shares during the period. Allen Investment Management LLC increased its holdings in shares of Abbott Laboratories by 1.0% during the first quarter. Allen Investment Management LLC now owns 11,711 shares of the healthcare product maker’s stock worth $924,000 after purchasing an additional 111 shares during the period. Demars Financial Group LLC increased its holdings in shares of Abbott Laboratories by 0.5% during the first quarter. Demars Financial Group LLC now owns 23,749 shares of the healthcare product maker’s stock worth $1,874,000 after purchasing an additional 113 shares during the period. Benjamin Edwards Inc. increased its holdings in shares of Abbott Laboratories by 57.0% during the first quarter. Benjamin Edwards Inc. now owns 314 shares of the healthcare product maker’s stock worth $25,000 after purchasing an additional 114 shares during the period. Finally, Beaumont Asset Management L.L.C. increased its holdings in shares of Abbott Laboratories by 3.8% during the first quarter. Beaumont Asset Management L.L.C. now owns 3,186 shares of the healthcare product maker’s stock worth $251,000 after purchasing an additional 117 shares during the period. 74.89% of the stock is currently owned by hedge funds and other institutional investors.

In related news, EVP Andrew H. Lane sold 80,000 shares of Abbott Laboratories stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $92.00, for a total transaction of $7,360,000.00. Following the completion of the transaction, the executive vice president now owns 107,090 shares of the company’s stock, valued at $9,852,280. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jared Watkin sold 8,248 shares of Abbott Laboratories stock in a transaction on Friday, March 6th. The stock was sold at an average price of $82.00, for a total transaction of $676,336.00. Following the transaction, the senior vice president now directly owns 68,696 shares of the company’s stock, valued at approximately $5,633,072. The disclosure for this sale can be found here. In the last quarter, insiders have sold 166,186 shares of company stock worth $15,359,524. 1.70% of the stock is owned by company insiders.

ABT has been the topic of a number of recent analyst reports. Raymond James lifted their price objective on shares of Abbott Laboratories from $92.00 to $102.00 and gave the company an “outperform” rating in a research note on Friday, April 17th. SVB Leerink decreased their price objective on shares of Abbott Laboratories from $102.00 to $93.00 and set a “market perform” rating on the stock in a research note on Wednesday, April 8th. Wells Fargo & Co lifted their price objective on shares of Abbott Laboratories from $95.00 to $107.00 and gave the company an “overweight” rating in a research note on Friday, April 17th. Credit Suisse Group reissued a “buy” rating and issued a $106.00 price objective on shares of Abbott Laboratories in a research note on Friday. Finally, Stifel Nicolaus lifted their price objective on shares of Abbott Laboratories from $85.00 to $108.00 in a research note on Friday, April 17th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $99.47.

Shares of NYSE:ABT traded up $1.08 during mid-day trading on Friday, reaching $91.47. 5,182,655 shares of the company’s stock were exchanged, compared to its average volume of 7,501,599. The firm has a market capitalization of $159.89 billion, a price-to-earnings ratio of 45.96, a PEG ratio of 3.75 and a beta of 0.98. The business’s fifty day moving average price is $90.01 and its 200-day moving average price is $85.74. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.01 and a current ratio of 1.43. Abbott Laboratories has a twelve month low of $61.61 and a twelve month high of $100.00.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.07. The company had revenue of $7.73 billion for the quarter, compared to analyst estimates of $7.47 billion. Abbott Laboratories had a net margin of 11.15% and a return on equity of 18.61%. Abbott Laboratories’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.63 earnings per share. Analysts predict that Abbott Laboratories will post 2.81 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 29th. Stockholders of record on Friday, May 8th will be issued a dividend of $0.08 per share. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.35%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 44.44%.

Abbott Laboratories Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Recommended Story: What is the yield curve?

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply